HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McGrath, Y. Articles by Morgan, B. P. Search for Related Content PubMed PubMed Citation Articles by McGrath, Y. Articles by Morgan, B. P.

Development of Adenovirus Vectors Encoding Rat Complement Regulators for Use in Therapy in Rodent Models of Inflammatory Diseases¹

Yvonne McGrath^*, Gavin W. G. Wilkinson, O. Brad Spiller^* and B. Paul Morgan^2,*

Departments of ^* Medical Biochemistry and Medicine, University of Wales College of Medicine, Cardiff, United Kingdom

C activation has been implicated in the pathogenesis of numerous inflammatory human diseases and disease models. A therapy based on C inhibition might therefore be of benefit to reduce inflammation and ameliorate disease. C inhibition in vivo can be accomplished by the delivery of soluble recombinant C regulators either systemically or directly to a target site, but effects are transitory. We have developed a strategy for the efficient delivery of the membrane-bound rat C inhibitors, CD59, Crry, and decay-accelerating factor (DAF), using replication-deficient adenovirus vectors with the intention of treating rat models of disease in which C is implicated. The adenovirus recombinants(RAd), RAdCD59, RAdCrry, and RAdDAF, respectively, have been tested for expression and function of the transgene in vitro. Infection of human fetal foreskin fibroblasts resulted in high levels of expression of each of the rat inhibitors. The constructs were also tested for inhibition of rat C-mediated cell lysis and C3b deposition. In a cell lysis assay, each inhibited to varying degrees of efficiency in the order RAdCD59 = RAdDAF > RAdCrry. In a C3b deposition assay, RAdDAF caused a greater reduction in C3b deposition than RAdCrry and RAdCD59 was ineffective. These agents, individually or in combination, provide the tools for testing the effects of prolonged inhibition of C at a target site on the progress of experimental models of disease.

This article has been cited by other articles:

				D. A. Fraser, C. L. Harris, R. A.G. Smith, and B. P. Morgan Bacterial expression and membrane targeting of the rat complement regulator Crry: A new model anticomplement therapeutic Protein Sci., October 1, 2002; 11(10): 2512 - 2521. [Abstract] [Full Text] [PDF]

				A. M. Mehl, M. Jones, M. Rowe, and P. Brennan Characterization of a CD40-Dominant Inhibitory Receptor Mutant J. Immunol., December 1, 2001; 167(11): 6388 - 6393. [Abstract] [Full Text] [PDF]